Clearside Biomedical, Inc.
CLSD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -59.1% | -78.9% | 661.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 82.9% | 89.4% | 51.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,650.7% | -335.2% | -203.9% | -1,519% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,971.1% | -913.6% | -352.9% | -2,387.6% |
| EPS Diluted | -1.14 | -0.87 | -1.65 | -1.445 |
| % Growth | -31% | 47.3% | -14.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |